A new expert consensus statement explores how providers can give birthing parents who are living with HIV the information they need to decide for themselves.
The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the perinatal HIV prevention guidelines on Dec. 20.
Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.
A reasonably understandable initial response to this important study could be “WTF”—but the forces that conspire to harm people of color and people living in poverty are persistent and intransigent.
While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.
Jan. 23, 2020: Neurocognitive benefits of cannabis use; how unquantifiable HIV in CSF correlates to executive function; updated findings on efavirenz and microcephaly; cost-efficacy of a specialized HIV care coordination team.
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.